Medicare Weight Loss Medication Update
Beginning July 1, 2026, eligible Medicare Part D beneficiaries may be able to access certain GLP-1 weight loss medications through the new Medicare GLP-1 Bridge Program. This short-term CMS demonstration program is designed to help qualifying patients receive covered obesity treatment medications with a $50 copay.
For many Medicare patients, access to prescription weight loss medications has been limited, confusing, or difficult to navigate. The Medicare GLP-1 Bridge Program creates a temporary pathway for eligible beneficiaries who are prescribed GLP-1 medications specifically to reduce excess body weight and maintain weight reduction.
Florida Surgery & Weight Loss Center provides physician-guided medical weight loss consultations throughout Florida and more than 20 states through secure telehealth appointments. Our team can help patients review eligibility, understand available GLP-1 options, verify insurance benefits, and prepare for prior authorization requirements when appropriate.
This guide explains how the Medicare GLP-1 Bridge Program works, which medications are included, who may qualify, how much patients may pay, and what Medicare beneficiaries should know before starting treatment.
Medicare GLP-1 Bridge Program: Quick Facts
Start Date
July 1, 2026
End Date
December 31, 2027
Patient Copay
$50 for eligible beneficiaries
Prior Authorization
Required from the prescribing provider
Which GLP-1 Medications Are Included?
At this time, the Medicare GLP-1 Bridge Program includes select FDA-approved weight loss medications when prescribed to reduce excess body weight and maintain weight reduction.
Injection and tablets
All formulations
KwikPen® formulation only
Important: The single-dose vial and single-dose pen formulations of Zepbound® are not included in the Medicare GLP-1 Bridge Program.
Medicare GLP-1 Bridge Program Video Overview
Watch the official Medicare GLP-1 Bridge Program video below for additional information about how the program works.
